Bristol Myers Squibb Co. has identified new substituted oxazolone protein-nucleic acid degraders acting as DNA-binding protein Ikaros (IKZF1) and zinc finger protein Helios (IKZF2), Aiolos (IKZF3) and Eos (IKZF4) degradation inducers reported to be useful for the treatment of cancer.